This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Arthur Tzianabos, Ph.D., to the position of Chief Scientific Officer. Dr. Tzianabos joins OvaScience from Shire Human Genetic Therapies, where he led the discovery and development of new therapeutics from concept through commercialization, as well as product expansion and business development efforts.
“Arthur’s success in driving major scientific discoveries through clinical development to commercialization, and his diverse technical background in cell biology, will make him an excellent addition to our team,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Arthur also shares our commitment to solving medical problems in areas of high unmet need. Together, we are determined to help women with infertility by developing new treatments, the first of which we plan to make available in the second half of 2014.”
Dr. Tzianabos brings to OvaScience more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joins OvaScience from Shire, where he most recently served as Senior Vice President and Head, Research and Early Development. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire’s acquisition of Transkaryotic Therapies, Inc. in 2005. Prior to Shire, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease, and was on the Board of Directors of bluebird bio and ArmaGen Technologies. He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.